Judith Cabrera-Anzures

Welwyn Garden City, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Journal: Lancet (London, England)

Published: February 02, 2026

Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-Analysis.

Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-Analysis.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: May 15, 2025

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Journal: NPJ digital medicine

Published: February 02, 2024

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.

Journal: Nature medicine

Published: June 30, 2023

Identifying prodromal symptoms at high specificity for Parkinson's disease.

Identifying prodromal symptoms at high specificity for Parkinson's disease.

Journal: Frontiers in aging neuroscience

Published: June 05, 2023

Trial of Prasinezumab in Early-Stage Parkinson's Disease.

Trial of Prasinezumab in Early-Stage Parkinson's Disease.

Journal: The New England journal of medicine

Published: August 03, 2022

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS).

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS).

Journal: Clinical and translational allergy

Published: February 03, 2022

Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.

Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.

Journal: Therapeutic innovation & regulatory science

Published: November 26, 2021

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.

Journal: Frontiers in neuroscience

Published: August 27, 2021

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.

Journal: Frontiers in neurology

Published: May 05, 2021

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Journal: Blood

Published: September 19, 2019

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Journal: Respiratory medicine

Published: July 21, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026